PRO-TECT Study (AFT-39) Electronic Patient Reporting of Symptoms During Cancer Treatment





Ethan Basch, MD, UNC Lineberger Comprehensive Cancer Center



- Symptoms are common among patients receiving treatment for advance cancers but go undetected or unaddressed up to half the time.
- Routine collection of electronic PROs have shown improvement in several areas of patient health in a large single site study (Basch 2017).
- PRO-TECT is designed to determine if advanced cancer patients at intervention sites have better clinical outcomes (longer survival, fewer ER visits and unplanned hospitalizations, and better quality of life and physical function) than usual care.

Aim 1: Determine whether systematic integration of electronic patient-reported symptoms into cancer care delivery improves meaningful patient-centered outcomes.

Aim 2: Elicit perspectives about benefit-burden tradeoffs for integrating PROs into clinical workflow from different stakeholders.

Aim 3: Identify barriers, facilitators, and strategies used by practices to integrate PROs into clinical workflow.

RATIONALE OBJECTIVE

PRO-TECT Study (AFT-39) Electronic Patient Reporting of Symptoms During Cancer Treatment


(PRO-TECT



Ethan Basch, MD, UNC Lineberger Comprehensive Cancer Center



National cluster randomized controlled trial to determine the value, acceptability, and feasibility of integrating PROs into routine community cancer




STUDY SCHEMA

PRO-TECT Study (AFT-39) Electronic Patient Reporting of Symptoms During Cancer Treatment






Ethan Basch, MD, UNC Lineberger Comprehensive Cancer Center



follow up

Patient Symptom Guide





TREATMENT PLAN / INTERVENTION

PRO-TECT Study (AFT-39) Electronic Patient Reporting of Symptoms During Cancer Treatment





Ethan Basch, MD, UNC Lineberger Comprehensive Cancer Center



Inclusion

- Age ≥ 21 years
- · Metastatic cancer of any type
- Receiving outpatient systemic cancer treatment for noncurative/palliative intent, including chemotherapy, targeted therapy, or immunotherapy
- Enrolled at any point during a course or cycle of treatment
- Understand English, Spanish or Mandarin Chinese

Exclusion

- · Cognitive deficits
- Currently in a therapeutic clinical trial
- Treated with curative intent
- Receiving hormonal therapy only
- Indolent lymphomas
- Leukemias

Early Results

- 52 sites across 25 states randomized.
- 1,096 patients enrolled of planned 1,200.
- 95% compliance for completing weekly PROs.
- ~40% of PROs trigger alerts to clinicians for severe or worsening symptoms.
- Pain (49%) and physical function (45%) were the most common.
- Over half of patients chose to weekly self-report via email (58%) and 42% chose automated calls to phone.

KEY ELIGIBILITY CRITERIA/EARLY RESULTS

PRO-TECT Study (AFT-39) Electronic Patient Reporting of Symptoms During Cancer Treatment





Ethan Basch, MD, UNC Lineberger Comprehensive Cancer Center



This trial (AFT-39) is funded by an award from the Patient-Centered Outcomes
Research Institute (PCORI)

To learn more or to open this trial at your site, e-mail: seriggsb@email.unc.edu

FUNDING SUPPORT

CONTACT US